Search results
Added:
7 months ago
ESC Congress 2025 - The opening day of ESC Congress 2025 delivered compelling new developments as updated clinical practice guidelines were released alongside a series of eagerly awaited Hot Line trials.Leading interventional cardiologists, Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (The King Fahd Armed Forces Hospital, SA) present focused overviews of the most significant Hot Line and Late…
View more
Added:
1 year ago
Join renowned interventional cardiologists Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) for an exclusive preview of ACC.25's most significant late-breaking science.This episode of View from the Thoraxcenter delivers authoritative analysis of pivotal cardiovascular trials set to revolutionize clinical practice and research. Elevate your conference…
View more
Added:
1 year ago
In this exclusive episode of the "Innovations in Cardiology" podcast series, host Dr Dipti Itchhaporia, past president of the American College of Cardiology, delves into the latest advancements in cardiovascular health. She is joined by Dr Valentin Fuster, a pioneer in the field, who shares invaluable insights into the impact of biological ageing, the connection between the heart and brain, and…
View more
Added:
1 year ago
ESC Congress 24 – Day 2 of the ESC Congress 2024 was packed with important data for cardiovascular practice.Interventional experts DrMirvat Alasnagand DrKhaled Al-Shaibi(King Fahd Armed Forces Hospital, SA) joined us to summarise the key take-home messages from hot line trials presented on day.Day 2 Highlights:00:24-03:02: NOTION-3: Percutaneous coronary intervention in patients undergoing…
View more
Added:
1 year ago
Unpack ACC.25's Top Trials with View from the Thoraxcenter!Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC 2025.In this thought-provoking ACC 2025 wrap-up, delve into the nuances of the most impactful trials, gaining insights into their implications for current practice and future research directions.00:36 -…
View more
Added:
2 years ago
Unpack ACC.24's Top Trials with View from the Thoraxcenter!Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC.24.In this thought-provoking ACC 2024 wrap-up, delve into the nuances of the most impactful trials, gaining insights into their implications for current practice and future research directions.00:29 -…
View more
Added:
2 weeks ago
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and…
View more
Added:
2 weeks ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Added:
1 week ago
ACC 26 - Dr Paul Sorajja (Banner Health in Phoenix, Phoenix, US) and Dr Lars Sondergaard (Chief Medical Officer and Divisional Vice President, Medical Affairs, Abbott) discuss the role of TriClip TEER in treating patients with severe tricuspid regurgitation and new data showcasing how TriClip TEER provides significant reduction in heart failure hospitalization relative to medical therapy.Drawing…
View more
Added:
5 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more